Dr. Andrew Kuykendall is an assistant member at Moffitt Cancer Center in the department of malignant hematology. He earned his M.D. from the University of Florida College of Medicine and completed an internal medicine residency at the University of South Florida, followed by a hematology and medical oncology fellowship at Moffitt Cancer Center/University of South Florida. He primarily focuses his clinical and research efforts on myeloproliferative neoplasms (MPNs), MDS/MPN overlap syndromes, and systemic mastocytosis. He is dedicated to developing novel disease-modifying therapies for these rare diseases. He is the primary investigator of numerous clinical trials and an active member of the Myeloproliferative Neoplasms Research Consortium — a collaborative effort aimed at improving therapeutic options for MPN patients by rationally and efficiently developing disease-modifying therapies.